↓ Skip to main content

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#31 of 3,607)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
41 news outlets
twitter
24 X users

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
Published in
Journal for Immunotherapy of Cancer, June 2022
DOI 10.1136/jitc-2022-004582
Pubmed ID
Authors

Michal Harel, Coren Lahav, Eyal Jacob, Nili Dahan, Itamar Sela, Yehonatan Elon, Shani Raveh Shoval, Galit Yahalom, Iris Kamer, Alona Zer, Ofer Sharon, David P Carbone, Adam P Dicker, Jair Bar, Yuval Shaked

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 19%
Student > Ph. D. Student 6 14%
Other 2 5%
Student > Doctoral Student 1 2%
Lecturer > Senior Lecturer 1 2%
Other 3 7%
Unknown 21 50%
Readers by discipline Count As %
Agricultural and Biological Sciences 6 14%
Biochemistry, Genetics and Molecular Biology 4 10%
Medicine and Dentistry 4 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Immunology and Microbiology 2 5%
Other 3 7%
Unknown 21 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 309. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2024.
All research outputs
#119,348
of 26,673,263 outputs
Outputs from Journal for Immunotherapy of Cancer
#31
of 3,607 outputs
Outputs of similar age
#3,654
of 451,275 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 141 outputs
Altmetric has tracked 26,673,263 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,607 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,275 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 141 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.